US2001022969A1PendingUtilityA1
Use of antibodies to block the effects of gram-positive bacteria and mycobacteria
Est. expiryDec 15, 2012(expired)· nominal 20-yr term from priority
A61P 31/04A61P 7/02A61P 15/00A61P 13/02A61P 11/00A61P 1/16A61K 39/395A61K 2039/545C07K 2317/77C07K 16/2896C07K 16/241A61K 2039/505A61K 38/00
45
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention concerns a method of treating bacteremia, sepsis and other forms of toxemia caused by Gram-positive bacteria and mycobacteria comprising administering a therapeutically effective amount of anti-CD14 antibody molecules. A therapeutic composition comprising anti-CD14 antibody molecules in a pharmaceutically acceptable excipient is also contemplated.
Claims
exact text as granted — not AI-modified1 . A method of ameliorating one or more symptoms of Gram positive bacterial or mycobacterial sepsis in a subject comprising administering to the subject a therapeutically effective amount of an antibody having the same immunoreactivity as an antibody produced by ATCC Accession No. HB11364 (28C5) or an immunoreactive fragment thereof.
Join the waitlist — get patent alerts
Track US2001022969A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.